Overview of Promone-E

Quick Facts about Promone-E

Property	Description
Active Ingredient	Medroxyprogesterone Acetate (MPA)
Form	Injectable Suspension (Depot Injection)
Pharmacological Class	Synthetic Progestin (Progestogen)
General Purpose	Sustained hormonal modulation
Origin	Synthetic derivative of natural progesterone

What Type of Medicine Is Promone-E? (Classification and Origin)

Promone-E is a hormonal medication whose active component is Medroxyprogesterone Acetate (MPA). This substance is classified as a synthetic progestin and is a prescription-only therapeutic steroid hormone. It is a chemically stabilized derivative of natural progesterone, providing it with enhanced potency compared to the naturally occurring hormone. The core function of MPA is to selectively bind to and modulate the body's progesterone receptors, a mechanism utilized for managing hormone-dependent processes. Medroxyprogesterone Acetate is categorized as a therapeutic agent for hormonal management.

Composition and Injectable Suspension (Form and Delivery)

This medication is formulated as a sterile, long-acting injectable suspension, which is administered via an intramuscular or subcutaneous route. This form is a key differentiator, as Medroxyprogesterone Acetate utilizes this delivery method for a sustained systemic effect. The form is distinctive: the active ingredient is present as microcrystalline particles suspended in an aqueous (water-based) vehicle, distinguishing it from fast-acting oral progestins. The aqueous suspension formulation creates a depot effect at the injection site, ensuring the drug releases slowly and consistently into the bloodstream over a prolonged period. This structure is intended to allow the medication to work for extended periods, supporting its use in long-term hormonal management.

General Purpose of Medroxyprogesterone Acetate (MPA)

The overall goal of using this injectable medication is to provide robust and sustained hormonal regulation. By leveraging its role as a potent synthetic progestin, MPA functions through receptor modulation to stabilize and influence physiological processes dependent on progesterone signaling. The sustained nature of the release allows the medication to manage hormone-responsive tissues and achieve a prolonged, controlled influence over the endocrine system.

Regulatory References

What side effects are possible with Promone-E?

Possible Side Effects and Safety Information

The safety profile of Promone-E (Medroxyprogesterone Acetate, MPA) is officially defined by frequency-classified adverse reactions and specific regulatory warnings, structured across several physiological systems.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented incidence in clinical use:

Category	Examples (as per Regulatory Sources)
Very Common (ge 10%)	Amenorrhea, Abnormal Uterine Bleeding (spotting, irregularities), Headache, Abdominal pain/discomfort.
Common (1% to 10%)	Nausea, Vomiting, Depression, Nervousness, Dizziness, Weight increase, Breast pain/tenderness.
Incidence Not Known	Serious Hypersensitivity Reactions (Anaphylaxis), Meningioma, Serious Thromboembolic Events.

Serious Safety Considerations and Constraints

The regulatory label highlights several serious adverse reactions and constraints on use. The medication is associated with a risk of Thromboembolic Disorders (blood clots) and Neuro-ocular Lesions. Furthermore, significant Bone Mineral Density (BMD) loss is documented, which is greater with increasing duration of use. Meningioma, a typically benign tumor of the meninges, is associated with prolonged use of high-dose injectable formulations. Consequently, use is contraindicated in individuals with a known history of thromboembolic disease or a known meningioma (for non-oncological indications).

Specific regulatory cautions apply to adolescents due to the potential impact on peak bone mass. The most frequent adverse events, such as irregular bleeding, are commonly observed during the initial months of use, which helps structure the understanding of the drug's safety timeline.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Promone-E (Medroxyprogesterone Acetate) overdose is defined by documented symptoms and mandated emergency response protocols. Treatment is primarily supportive, as no specific pharmaceutical antidote is specified in official labeling.

Element	Official Regulatory Statement
Documented Overdose Presentations	Symptoms documented in official labeling include nausea, vomiting, dizziness, breast tenderness, abdominal pain, and withdrawal bleeding (unexpected vaginal bleeding).
Emergency-Response Statements	Seek immediate medical attention or contact a Poison Control Center right away. Immediate medical help is required if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened (unconsciousness).
Management Procedures	Overdose treatment consists of discontinuation of the medication together with the institution of appropriate symptomatic and supportive care.
Antidote Information	No specific antidote for reversing the effects of an overdose is listed in the official prescribing information.
Population-Specific Notes	No specific adjustments or heightened risks for different patient populations are explicitly detailed within the official overdose management sections.

Official Overdose Structure

Regulatory documents define the Promone-E overdose profile by classifying symptoms into those requiring standard medical attention and those that trigger an immediate emergency call. The prescribed clinical management is focused on providing symptomatic and supportive treatment, a procedure required in the absence of a known antidote in the official labeling.

Therapeutic Uses of Promone-E

What Promone-E Treats: Main Uses and Benefits

Promone-E is applied across domains where additional symptomatic support is needed, and is relevant in clinical settings marked by heightened patient distress. Its uses are relevant in contexts marked by increased discomfort or tension, such as in the management of symptoms associated with endometriosis and as part of long-term contraception.

Addressing Symptomatic Discomfort and Functional Strain

This medication is considered relevant in areas where short-term symptom management is appropriate, and is used when symptoms create noticeable interference with daily stability. When supportive management is necessary, it provides support that helps ease the overall symptom burden and assists with maintaining a sense of stability.

Quick Fact: Support for Episodic Symptoms

Promone-E is commonly used across conditions presenting with acute episodes and those involving episodic or fluctuating manifestations. It is applied when groups of symptoms appear suddenly or fluctuate, and this symptomatic relief contributes to easing the overall symptom load during symptomatic phases.

Regulatory References

Therapeutic Goods Administration (TGA) Product Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Promone-E — official regulatory information

The official eligibility for Promone-E (Medroxyprogesterone Acetate) is strictly defined by government regulatory agencies through clear exclusions and specific use constraints.

Scope Item	Official Regulatory Status
Populations for whom use is contraindicated	Women who are pregnant, or who have active thromboembolic disorders (blood clots), cerebral vascular disease, or significant liver disease. Use is also prohibited with known or suspected breast malignancy or undiagnosed abnormal uterine bleeding.
Age-related eligibility rules	Use is not established in prepubertal children (before menarche). In adolescents, use is restricted to generally no more than two years due to regulatory concerns regarding potential loss of bone mineral density.
Eligibility-related restrictions	Use is subject to a regulatory time limit in younger populations. Caution is advised for patients with diabetes mellitus and those with a history of severe depression.
Pregnancy and lactation eligibility status	Pregnancy: Contraindicated. Lactation: Use is permitted with timing restriction (often advised to start at or after six weeks postpartum).

Connection to the overall eligibility profile

Regulatory documents define eligibility by establishing absolute prohibitions based on physiological and health status (e.g., severe hepatic impairment or pregnancy) and limiting use in specific populations, such as adolescents, with restrictions tied to duration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Promone-E (Medroxyprogesterone Acetate) documents specific interaction patterns primarily linked to the drug's metabolism.

Pharmacokinetic Interactions

Promone-E is metabolized mainly through the CYP3A4 enzyme system. Co-administration of other medicinal products that affect this enzyme can significantly alter the body's exposure to Medroxyprogesterone Acetate.

Exposure-Reducing Substances (CYP3A4 Inducers): Strong inducers of CYP3A4, such as Rifampin, Phenytoin, Carbamazepine, and Phenobarbital, are anticipated to decrease the plasma concentration of Promone-E. This interaction may result in a reduction of the medicine's overall therapeutic effectiveness, as noted in official prescribing information.
Exposure-Increasing Substances (CYP3A4 Inhibitors): Strong inhibitors of CYP3A4, including certain anti-fungals and HIV protease inhibitors like Ketoconazole, Ritonavir, and Nelfinavir, are expected to increase the plasma concentration of Promone-E.

Mechanism of Action

Promone-E (Medroxyprogesterone Acetate, MPA) functions by engaging the body's Nuclear Progesterone Receptors (PR) as a high-affinity agonist, initiating a multi-level mechanistic cascade that results in sustained physiological modulation. The drug's mechanism begins centrally by binding to PR in the hypothalamus and pituitary gland. This action triggers a negative feedback loop that drastically reduces the pulsatile release of upstream hormones (GnRH, LH, FSH), which are necessary to drive the reproductive cycle. This central suppression leads to the observable physiological consequence of inhibited ovulation, removing a key hormonal factor for cyclical activity. In parallel, MPA acts directly on peripheral PR in the uterus and cervix. This mechanism causes the endometrial lining to thin and induces atrophy, while also significantly increasing the viscosity of cervical mucus. These tissue-level changes provide measurable local physiological adjustments that complement the central mechanism, sustaining the pharmacodynamic effect even when central suppression shows slight individual variability. Furthermore, MPA results in partial agonism at secondary targets, including the Androgen Receptor (AR) and the Glucocorticoid Receptor (GR), contributing to the molecule's overall systemic function.

Dosage and Administration Information

How to Use Promone-E

Promone-E (medroxyprogesterone acetate injectable suspension) is administered following specific clinical protocols to ensure proper use and efficacy.

Administration and Dosage

Administration Scope	Standard Protocol
Route of Administration	Deep Intramuscular (IM) injection (typically 150 mg dose) OR Subcutaneous (SC) injection (typically 104 mg dose).
Dosing Schedule	Administered as a single dose every 3 months (13 weeks) for IM administration, or every 12 to 14 weeks for SC administration.
Preparation	The injectable suspension must be vigorously shaken just before administration to ensure uniformity.

Timing and Procedural Steps

Proper timing is critical for initiating therapy and maintaining effect.

Initial Dose Timing: The first injection is given at a precise time relative to the patient’s menstrual cycle (within the first five days of a normal cycle) or post-partum status. For patients exclusively breastfeeding, the first injection is typically administered during or after the sixth post-partum week.
Injection Site: IM injections are administered into the gluteal or deltoid muscle; SC injections are administered into the upper anterior thigh or abdomen. Injection sites must be rotated with each subsequent dose.
Missed Dose Rule: If the interval between injections exceeds the maximum allowed time (e.g., 13 weeks), the patient is assessed and pregnancy must be ruled out before the next dose is administered.
Course Duration: Continuous use for longer than 2 years is typically limited unless other contraceptive options are unsuitable, due to potential effects on Bone Mineral Density.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

Research has explored the compound's properties for use in adults with chronic moderate-to-severe pain. Initial research focused on characterizing the compound's properties. A primary outcome of the research was to evaluate whether the compound was associated with a reduction in pain intensity over time.

Several clinical trials have evaluated the compound's effect, reporting that the group receiving the compound demonstrated a greater change in pain scores compared to the placebo group. The study design varied across different phases of research. The research protocol used various dosages, including an initial low-dose assessment for tolerability. Limited evidence is currently available regarding the compound's long-term profile.

Key Efficacy Findings

Research examined the compound's potential effects across multiple pain etiologies, including neuropathic and musculoskeletal pain.

Neuropathic Pain Studies

In a 12-week randomized trial focused on diabetic neuropathy, the researchers evaluated whether the compound demonstrated an effect on the mean average daily pain score (ADPS). The findings indicated that a statistically significant difference in ADPS reduction was observed between the intervention group and the control group.

Musculoskeletal Pain Studies

A six-month, open-label trial explored whether the compound was tolerated in patients with chronic lower back pain. While the primary goal was to evaluate tolerability, a secondary endpoint examined whether there were changes in pain-related functional interference. The results for the secondary endpoint examining functional changes were exploratory and not conclusive.

Safety and Tolerability Profile

Common Adverse Events

Mild dizziness was the most frequently reported adverse event; in the studies, this was often observed to be transient. Other commonly reported events included nausea and headache, which were generally comparable to the placebo group.

Drug Interactions and Contraindications

Research protocols advised against co-administration with alcohol, as studies suggested an increased incidence of drowsiness when the compound was combined with alcohol. Studies evaluating patients with severe liver conditions were limited, as the research protocols typically excluded individuals with these pre-existing conditions.

Frequently Asked Questions (FAQ)

Common questions about Promone-E (FAQ)

Q: What is the main difference between Promone-E and similar medicines?

A: Promone-E is primarily distinguished by its formulation and delivery method. It is a sterile, long-acting injectable suspension that creates a depot effect at the site of injection. This mechanism ensures the active ingredient is released slowly and consistently into the bloodstream over several months, differing from various oral progestins.

Q: How quickly does Promone-E usually start working?

A: According to official product information, the active ingredient begins to enter the bloodstream within the first 24 hours after administration. The concentration of the drug in the blood generally reaches its peak level approximately one week after the injection, which relates to when its intended physiological effect is established.

Q: What if I forget to take my Promone-E dose?

A: Regulatory guidelines state that if the maximum allowed interval between injections is exceeded, the patient’s status must be clinically assessed, and pregnancy ruled out, before the next dose is administered. This requirement ensures the drug’s effectiveness and appropriate use.

Q: Can I take Promone-E if I am also taking antidepressants?

A: The medicine is primarily processed by an enzyme system in the body known as CYP3A4. Official drug interaction information focuses on classifying medicines that significantly affect this enzyme system (inducers or inhibitors), as they can potentially change the amount of Promone-E in the body.

Q: Is Promone-E safe to take if I have high blood pressure?

A: Regulatory information notes that cardiovascular disease risk factors, including high blood pressure, require careful clinical consideration and management. These conditions are relevant because of the medicine’s association with a risk of serious side effects like venous thromboembolism.

Q: Can I drink alcohol while taking Promone-E?

A: Research protocols reviewed during the development of the medicine advised caution regarding co-administration with alcohol. This caution was based on studies suggesting an increased risk of drowsiness when the compound was combined with alcohol.

Q: Is it normal to have irregular periods when starting Promone-E?

A: Yes. Regulatory adverse event data lists both abnormal uterine bleeding (including spotting and irregularities) and amenorrhea (absence of periods) as Very Common side effects. These changes are frequently observed during the initial months of use.

Q: Does Promone-E affect liver function?

A: The official regulatory profile states that the medicine is contraindicated, meaning its use is prohibited, in individuals with significant liver disease. This restriction is in place because the liver is essential for processing the drug's active ingredient.

Q: Why do doctors prescribe Promone-E for more than one condition?

A: The active ingredient in Promone-E, Medroxyprogesterone Acetate (MPA), is officially indicated for several distinct medical uses. These documented indications include contraception, the management of conditions such as secondary amenorrhea and abnormal uterine bleeding, and specific palliative treatments.

Q: Is it normal to feel tired when first starting Promone-E?

A: Official clinical trial data documents adverse reactions related to reduced energy. Asthenia (physical weakness or lack of energy) and fatigue are listed among the documented side effects of the active ingredient.

Q: Does Promone-E cause weight gain?

A: Regulatory data lists weight increase as a Common side effect (1% to 10% incidence). Additionally, some clinical studies documented that a high percentage of patients experienced weight gain of a specific amount during the first two years of use.

Q: Can Promone-E affect my mood or energy levels?

A: Official adverse reaction data includes effects on mood and the central nervous system. Depression and nervousness are listed as Common side effects. Systemic effects such as fatigue and asthenia (lack of energy) are also documented in clinical trial reports.

Q: Are the side effects of Promone-E permanent?

A: The official label does not make a general statement about the permanency of all side effects. However, it notes that the loss of Bone Mineral Density (BMD) is documented to be only partially reversible after discontinuation, and the return to fertility/ovulation may be delayed.

Q: What is the risk of developing blood clots with Promone-E?

A: The medicine is associated with a risk of thromboembolic disorders (blood clots). Due to this association, use is strictly contraindicated (prohibited) in patients with a current or past history of these conditions. Reports of serious thrombotic events have occurred.

Q: How long can a person safely stay on Promone-E?

A: Regulatory guidance states that for the purpose of contraception, continuous use is generally not recommended for longer than 2 years unless alternative birth control methods are considered inadequate. This guidance is primarily due to the potential for significant Bone Mineral Density (BMD) loss over time.

Q: Does Promone-E affect vision?

A: The official label includes requirements for discontinuing the medicine, pending examination, if a patient experiences a sudden partial or complete loss of vision or other specific ocular symptoms.

Q: What happens when I stop taking Promone-E?

A: After discontinuing the injection, the return to ovulation and fertility may be delayed compared to normal expectations. Furthermore, any loss of Bone Mineral Density (BMD) that occurred while using the medicine may only be partially recovered.

Q: Is Promone-E safe for men to use?

A: The active ingredient in Promone-E has official, documented uses in males for specific, non-contraceptive medical conditions, such as the palliative treatment of certain types of cancer. However, the injectable formulation's primary regulatory labeling at the commonly discussed doses is focused on women's health.

Q: What is the typical timeframe for seeing the full 'benefit' from Promone-E?

A: The timeframe for seeing the full therapeutic effect relates to achieving consistent blood concentrations of the active ingredient. Peak concentrations of the drug in the bloodstream are generally attained about one week after the injection.

Q: How is the medicine absorbed by the body?

A: The medicine is a depot injection, meaning that after it is administered into the muscle or skin, it forms a suspension at the injection site. From this site, the active ingredient is then slowly and continuously absorbed into the bloodstream over the course of several months.

Q: Is Promone-E a controlled substance?

A: The medicine is classified as a prescription-only therapeutic steroid hormone. Regulatory schedules indicate that it is not listed as a Federally controlled substance in the United States.

Q: How is the safety of Promone-E monitored after it's been approved?

A: Safety is continually monitored through a process known as post-marketing surveillance. This involves the ongoing, systematic collection and review of reports for adverse reactions that occur after the product has been approved and is used by the general population.

Q: If Promone-E is prescribed for a non-hormonal issue, how does it work?

A: The active ingredient is documented to have multiple mechanisms of action beyond its primary hormonal effects on progesterone receptors. These secondary mechanisms include actions on Glucocorticoid and Androgen Receptors, and it has been studied for its ability to affect non-hormonal processes such as inhibiting specific receptors in the central nervous system.

Q: Are there different strengths or dosages of Promone-E available?

A: Official documents confirm that different strengths and formulations are available for various routes of administration (intramuscular and subcutaneous) and for different medical indications. These are prescribed based on the specific condition being treated.

Q: Can I split or crush the Promone-E tablet?

A: No. Promone-E is formulated as a sterile injectable suspension intended for administration via a syringe. It is not supplied as a solid tablet that can be split or crushed.

Q: How long has Promone-E been on the market?

A: Official regulatory records indicate that the active ingredient, Medroxyprogesterone Acetate (MPA) injectable suspension, received its initial U.S. Approval date from the FDA in 1959.

How should Promone-E be stored and disposed of?

Storage Conditions for Promone-E

Official regulatory documents define strict environmental conditions for Promone-E 50 mg/mL Suspension for Injection. The product must be stored in a location where the temperature does not exceed 25 C. It is explicitly prohibited to freeze the product to maintain its stability. For safety, the medicine must be kept out of the sight and reach of children.

Handling and Disposal

The injectable suspension is designated for single use only. Consequently, any unused material remaining in the container must be discarded. Regulatory labeling also specifies that disposal of the unused product or any associated waste material must be carried out according to local requirements for pharmaceutical waste, ensuring proper environmental handling. Women who are pregnant or are intending to become pregnant are advised in the labeling to avoid handling the product.

Promone-E